Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BRISTOL-MYERS SQUIBB TOP R&D POSITION WILL BE HELD BY EDGAR HABER, MD

Executive Summary

BRISTOL-MYERS SQUIBB TOP R&D POSITION WILL BE HELD BY EDGAR HABER, MD, who will hold the title of president of Bristol-Myers Squibb Pharmaceutical Research Institute. His responsibilities will include Bristol-Myers Pharmaceutical R&D Division, Oncogen, and Squibb Institute for Medical Research, Bristol-Myers Squibb announced March 20. Haber had been head of the Squibb Institute for Medical Research since January 1988. Prior to joining Squibb, Haber was chief of cardiology at Mass General for 24 years. Haber had also been a professor at Harvard Medical School. Haber will report directly to his boss at Squibb -- Bristol-Myers Squibb President Richard Furlaud. William Comer, PhD, who had headed the Bristol-Myers Pharmaceutical R&D Division, has been appointed to Bristol-Myers Squibb senior VP-strategic management, reporting to Wayne Davidson, president of Bristol-Myers Squibb Pharmaceutical and Nutritional Group, the company announced March 21. Although Comer apparently headed Bristol-Myers R&D in 1989, the company announced that appointment in December ("The Pink Sheet" Jan. 1, 1990, "In Brief"), several months after the merger was finalized. * In addition, the company said that the still separate pharmaceutical R&D functions "within the operating units of the Bristol-Myers Squibb Pharmaceutical Research Institute will be integrated more completely during the second quarter of this year." Bristol-Myers Squibb also announced the formation of an operating committee of the company's pharmaceutical research institute. The committee will include: Stephen Carter, MD, who replaces Comer as president of Bristol-Myers Pharmaceutical Research and Development Division and will be responsible for worldwide clinical development; George Todaro, MD, president of Oncogen, who will also assume responsibilities for exploratory pharmaceutical research; Andrew Bodnar, MD/JD, senior VP and chief operating officer of the Squibb Institute, who will be responsible for administrative and planning functions; Kenneth Given, MD, senior VP-worldwide medical and regulatory affairs at the Squibb Institute, who will be responsible for worldwide regulatory affairs; and William Scott, PhD, senior VP-molecular and cellular biology at the Squibb Institute, responsible for drug discovery.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS017142

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel